a public good project by the
Synthesis
Company
of California

© 2026

Metoprolol ?-hydroxylation is a poor probe for debrizoquine oxidation (CYP2D6) polymorphism in Jordanians | doi.page

0 citations0 references

Google Scholar doi.org

Metoprolol ?-hydroxylation is a poor probe for debrizoquine oxidation (CYP2D6) polymorphism in Jordanians

European Journal of Clinical Pharmacology·1994·Vol. 47(4), pp. 311–4

Citations Over TimeTop 18% of 1994 papers

H. F. Al-Hadidi, Yacoub M. Irshaid, N. M. Rawashdeh

Related Papers

→ The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients(2006)58 cited
→ The relationship between plasma concentration of metoprolol and CYP2D6 genotype in patients with ischemic heart disease(2014)7 cited
→ Development of a Physiologically Based Pharmacokinetic Model for Metoprolol in Different CYP2D6 Genotypes(2020)1 cited
Polymorphism of CYP2D6 gene and the influence on the metabolism of metoprolol(2011)
→ The relationship between plasma concentration of metoprolol and CYP2D6 genotype in patients with ischaemic heart disease(2013)